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Members of the interleukin-1 (IL-1) family are important mediators of obesity and metabolic
disease and have been described to often play opposing roles. Here we report that the
interleukin-36 (IL-36) subfamily can play a protective role against the development of dis-
ease. Elevated IL-36 cytokine expression is found in the serum of obese patients and
negatively correlates with blood glucose levels among those presenting with type 2 diabetes.
Mice lacking IL-36Ra, an IL-36 family signalling antagonist, develop less diet-induced weight
gain, hyperglycemia and insulin resistance. These protective effects correlate with increased
abundance of the metabolically protective bacteria Akkermansia muciniphila in the intestinal
microbiome. IL-36 cytokines promote its outgrowth as well as increased colonic mucus
secretion. These findings identify a protective role for IL-36 cytokines in obesity and meta-
bolic disease, adding to the current understanding of the role the broader IL-1 family plays in
regulating disease pathogenesis.
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Over the past 40 years, global levels of obesity have morethan doubled. As obesity predisposes to the metabolicsyndrome and has been definitively linked to coronary
heart disease, stroke, type 2 diabetes and certain forms of cancer,
this growing epidemic represents one of the most significant
current global health challenges.
In tandem with the emergence of this problem has been an
increase in understanding the pathological mechanisms which
link the obese state to the development of disease. Central to these
mechanisms is the heightened state of systemic inflammation as a
result of obesity. Since the seminal observations made by Hota-
misligil et al., demonstrating the role of adipose tissue-derived
TNF as an inhibitor of insulin signalling and first linking obesity-
driven inflammation to type 2 diabetes1, it is now recognised that
the nature of adipose tissue inflammation is a major contributor
towards obesity-related diseases2–4. Further complexity is added
through the instructive role of the gastrointestinal immune sys-
tem in influencing the development of inflamed adipose tissue. It
is now evident that changes in the homoeostatic barrier function
of the gut can play a major role in the development of systemic
inflammation in obesity5. In this context, it is perhaps unsur-
prising that the constituents of the intestinal microbiome are also
emerging as an important factor in this regard. In healthy indi-
viduals, the gastrointestinal immune system plays an immuno-
surveillant role, in constant interaction with the intestinal
microbiome which profoundly influences its activity. The role of
the microbiota in the development of obesity-driven metabolic
disease first emerged from studies on germ-free mice, which
demonstrated reduced levels of experimental weight gain and
improved glucose tolerance6,7. Moreover, the transfer of an
‘obese’ microbiome to germ-free mice can lead to significant
increases in adiposity confirming the important instructive role in
contributing to disease8. Similarly, changes in the composition of
the intestinal microbiome have been associated with obesity and
the development of metabolic disease in humans9,10. As well as
contributing to obesity and disease, it is also becoming apparent
that certain constituents of the microbiota can act opposingly to
restrict adiposity. In recent times, it has been demonstrated that
the presence of the bacteria Akkermansia muciniphila in the
intestinal microbiome can act directly to suppress weight gain
and impaired glucose tolerance in mice11. Many of these pro-
tective effects have now been recapitulated using a purified outer
membrane protein, Amuc_1100, derived from A. muciniphila12.
It is also noteworthy that several dietary interventions targeting
obesity and glucose intolerance, and the glucose-lowering drug
metformin, increase A. muciniphila abundance11,13–15. Sig-
nificantly, follow-up studies have also demonstrated a clear
association between the relative abundance of this bacterium in
the microbiome and the metabolic health of obese patients16.
Such observations suggest that the composition of the intestinal
microbiome can be altered towards a more ‘healthy’ lean state,
highlighting its potential as a therapeutic strategy, and placing the
identification of the mechanistic pathways which can alter the
composition of the microbiota as a particular area of interest.
In this study, we identify the IL-36 family of cytokines as one
such pathway. The IL-36 family of cytokines are a recently
described subset of the larger IL-1 family which are emerging as
important mediators of obesity-related metabolic disease17. The
family consists of three separate agonistic ligands, designated IL-
36α, IL-36β and IL-36γ, and a specific IL-36 receptor antagonist
(IL-36Ra), all of which act through a specific IL-36 receptor18.
Similar to the more extensively characterised ‘classical’ IL-1 cyto-
kines, IL-1α and IL-1β, IL-36 cytokines are thought to act as
important mediators of homoeostasis and inflammation, but in a
more tissue-restricted manner. In this role, IL-36 cytokines are
known to play a central role in orchestrating psoriatic inflammation
in the skin and can also act as mediators of gastrointestinal
inflammation and homoeostasis19–23. In contrast to these estab-
lished roles of the IL-36 family, little information is available con-
cerning how, and if, this cytokine family may influence obesity-
induced systemic inflammation leading to metabolic syndrome.
Related IL-1 family members have previously been studied in this
context revealing opposing functions17,24. For example, IL-1β has
long been implicated in the pathogenesis of both type 2 diabetes
and atherosclerosis, and Canakinumab (anti-IL-1β-neutralising
monoclonal antibody) is currently the focus of extensive clinical
investigation for these indications17. In direct contrast, IL-18 and
IL-33 have been demonstrated to play a protective role in animal
models of obesity-driven metabolic syndrome, although the precise
mechanisms through which this occurs have not been
identified17,24. Moreover, there are currently no data to indicate that
the microbiome may play a role in these protective effects.
In this study, we demonstrate that IL-36γ expression is increased
in the serum of clinically obese patients and these elevated
expression levels are negatively correlated with both haemoglobin
A1c (HbA1c) and fasting blood glucose (FBG) levels among
patients with type 2 diabetes indicating a protective role for these
cytokines in countering metabolic dysfunction. These protective
effects are mirrored in mice with a deficiency in the IL-36 receptor
antagonist (Il36rn−/−), which exhibit reduced weight gain and
metabolic dysfunction. Mechanistically, the protective effects occur
in association with the relative outgrowth of the commensal bac-
terial strain A. muciniphila in the intestinal microbiome which is
facilitated through IL-36-mediated enhanced mucus secretion in
the colon.
Results
Elevated IL-36 cytokine expression among obese patients. In an
effort to determine whether the IL-36 family of cytokines may play a
role in the development of obesity and metabolic disease, we
investigated serum expression levels of the IL-36 family among a
cohort of adult patients presenting with clinical obesity (BMI>30 kg/
m2), with or without signs of diabetes, as determined by serum
HbA1c levels, according to American Diabetes Association guide-
lines25. Expression of all IL-36 family ligands was detected among a
small number of lean patients. Interestingly, levels of IL-36γ alone
were found to be specifically and significantly elevated among obese
patients when compared with healthy lean control subjects (Fig. 1c).
These elevated levels were observed among obese patients irre-
spective of whether they exhibited evidence of type 2 diabetes (i.e.
HbA1c ≥ 48mmol/mol), indicating that elevated IL-36γ expression
is directly associated with the obese phenotype. In contrast, no such
differences were observed in the expression levels of the other
agonistic ligands, IL-36α and β (Fig. 1a, b). Expression of the IL-36
receptor antagonist was low or not detected among all subjects
examined (Fig. 1d).
To further determine what impact, if any, increased IL-36γ might
play in the pathogenesis of obesity and metabolic disease, we
examined whether elevated expression levels were correlated with
established clinical and biochemical parameters of disease recorded
for each patient subgroup. These parameters included sex, age, BMI,
weight in kg, HbA1c and FBG levels, as well as serum lipid levels
including cholesterol, triglycerides, LDL and HDL (Supplementary
Table 1). Interestingly, this analysis revealed a strong negative
correlation between blood glucose levels as determined by both
HbA1c (r=−0.74, p= 0.0015) and FBG (r=−0.54, p= 0.03), and
serum levels of IL-36γ, specifically among obese patients with type 2
diabetes (HbA1c ≥ 48mmol/mol) (Fig. 1e, f). No such correlation
was found to exist among obese patients that did not have diabetes,
with HbA1c levels less than the 48mmol/mol cut-off (Fig. 1g, h).
These data demonstrate that elevated IL-36γ levels are associated
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with lower blood glucose levels among obese patients with diabetes
and indicate that IL-36 cytokines may act to promote metabolic
health in obesity.
Reduced obesity and metabolic disease in Il36rn−/− mice. To
gain a greater understanding of how the IL-36 family of cytokines
might impact the pathogenesis of obesity and metabolic disease,
we examined mice deficient in the Il36rn gene which encodes the
IL-36 receptor antagonist19. Interestingly, under normal chow-
feeding conditions, these mice exhibited progressively less weight
gain compared with wild-type control mice (wt), which was
evident by 6 months of age (Fig. 2a), despite similar levels of food
consumption (Fig. 2b). This decreased weight gain was associated
with a lower mass of both epidydimal (EAT) and subcutaneous
(SAT) white adipose tissue depots (Fig. 2c). Furthermore,
Il36rn−/− mice were found to have significantly improved glu-
cose tolerance and lower insulin resistance at 10 months of age
over their wt counterparts (Fig. 2d–g), demonstrating that loss of
expression of the IL-36 receptor antagonist leads to a decrease in
normal weight gain and the spontaneous development of glucose
















































































































































Fig. 1 IL-36 cytokine expression levels in the serum of obese patients. a–d IL-36α, β, γ and IL-36Ra levels in the serum of lean individuals (n= 37), obese
non-diabetic patients (HbA1c < 48) (n= 51) and obese with diabetes (HbA1c≥ 48) (n= 16), as measured by ELISA. e–h Correlation analysis of IL-36γ
levels with HbA1c and FBG in the serum of diabetic obese patients (e, f) and non-diabetic obese patients (g, h). Spearman correlation coefficient (r) and the
corresponding p value shown. For (a–d) data are shown as means ± SEM, statistical analysis by two-tailed Mann–Whitney test, **p < 0.01, ****p < 0.0001.
DM: diabetes mellitus. Source data are provided as a Source Data file
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mice (2 months old), with comparable starting weights to their
wild-type counterparts, exhibited significantly less weight gain
and adipose tissue accumulation when placed on a high-fat diet
(HFD) (60 kcal% fat) for 8–10 weeks (Fig. 3a, c). Again, this
occurred in the absence of any alteration in daily food intake
(Fig. 3b). These mice also displayed significant protection from
HFD-induced metabolic dysfunction as determined by their
fasting serum insulin levels, which were significantly lower in the
Il36rn−/− mice (Fig. 3h), as well as glucose and insulin tolerance
tests (Fig. 3d–g). In addition, Il36rn−/− mice exhibited increased
Akt phosphorylation in the liver, after insulin challenge, indi-
cating enhanced insulin sensitivity in this tissue compared with
wt mice (Fig. 3i, j). Phosphorylation of the insulin receptor β (IR)
also appeared to be slightly higher in the liver of the Il36rn−/−
mice, albeit not to a significant extent (Fig. 3i, j). No differences in
insulin sensitivity were detected in either muscle or EAT under
these conditions (Fig. 3i, k, l). These data indicate that unrest-
ricted IL-36 cytokine signalling, through deficiency of the IL-36
receptor antagonist, suppresses weight gain and the development
of metabolic dysfunction in a diet-induced obesity mouse model.
In contrast, mice with a global deficiency in Il1rl2, the gene
encoding the IL-36 receptor, exhibited normal weight gain and
comparable levels of glucose and insulin tolerance to those
observed in wt mice after 8–10 weeks exposure to HFD
(Supplementary Fig. 1). Together, these data suggest that while
constitutive expression of the IL-36 receptor does not play a role
in HFD-induced adiposity in mice, hyperactive IL-36 family
activity can protect against obesity and metabolic disease.
The intestinal microbiome is altered in Il36rn−/− mice. As we
observed that IL-36 receptor antagonist deficiency improves
glucose tolerance in mice, we next examined whether adipose
tissue inflammation induced upon exposure to HFD was altered
in this setting (Supplementary Fig. 2). Although the absolute
numbers of adipose tissue infiltrating CD45+ cells were reduced
in Il36rn−/− mice after 10 weeks exposure to HFD (Supple-
mentary Fig. 2a), as were the numbers of F4/80+ CD11b+ total
macrophages (Supplementary Fig. 2b) and F4/80+ CD11b+
CD11c+ CD301− M1 macrophage subset (Supplementary Fig.
2c), these differences were not evident when analysed per gram of
adipose tissue indicating that Il36rn deficiency did not quantita-
tively affect the degree of CD45+ cell infiltration observed
(Supplementary Fig. 2e). In addition, no differences in the relative
numbers of infiltrating pathogenic or homoeostatic macrophage











































































































































Fig. 2 Il36rn−/− mice are protected from spontaneous weight gain and metabolic dysfunction. a–e Male Il36rn−/− and wt control mice of the same age
were kept on normal chow diet up to 12 months of age (n= 5 per group). Weights (a) and daily food intake per mouse (b) were monitored over time from
2 months of age. c EAT and SAT depots mass was measured at 12 months of age. d, e Intraperitoneal glucose tolerance test (GTT) performed at 9 months
of age; glucose measurements over time after glucose bolus-injected i.p. (d) and area under curve (AUC) (e) shown. f, g Intraperitoneal insulin tolerance
test (ITT) performed at 9 months of age; glucose measurements over time after insulin bolus-injected i.p. (f) and AUC (g) shown. Data represent means ±
SEM. Statistical analysis using two-tailed unpaired student’s t-test, or RM two-way ANOVA with Bonferroni’s correction for multiple comparisons for (a),
(d) and (f). ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file
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Fig. 3 Il36rn−/− mice are protected from diet-induced obesity and insulin resistance. a–h Male Il36rn−/− and wt mice of the same age were fed a HFD
(60 kcal% fat) for 8–10 weeks starting from 8 weeks of age. Weights (a) and daily food intake per mouse (b) were monitored and data shown are pooled
from three independent experiments (wt n= 15, Il36rn−/− n= 22). c EAT and SAT depots mass was measured after 10 weeks in HFD. d, e Intraperitoneal
GTT on wt and Il36rn−/− mice after 8 weeks in HFD; glucose over time after i.p. glucose injection (d) and AUC (e) shown. f, g Intraperitoneal ITT on wt
and Il36rn−/− mice after 9 weeks in HFD; glucose over time after insulin bolus-injected i.p. (f) and AUC (g) shown. h Fasting blood insulin levels for wt
and Il36rn−/− mice after 10 weeks in HFD. i Relative protein expression levels of phospho-Akt (P-Akt)/total Akt (T-Akt) and phospho-insulin receptor β
(P-IR)/total insulin receptor β (T-IR) in the liver, skeletal muscle and EAT of wt (n= 7) and Il36rn−/− (n= 4) mice after insulin injection, as indicated by
densitometry analysis of western blot data (in Source Data file). j–l Protein expression of P-IR, T-IR, P-Akt and T-Akt in the liver (j), skeletal muscle (k) and
EAT (l) of representative wt (n= 3) and Il36rn−/− (n= 3) mice after insulin injection. Data represent means ± SEM. Statistical analysis using two-tailed
unpaired student’s t-test for (c), (g) and (i), two-tailed Mann–Whitney test for (b), (h) and (e) and RM two-way ANOVA for (a), (d) and (f). ns p > 0.05,
*p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file
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Il36rn deficiency does not significantly alter the inflammatory
profile of adipose tissue induced by exposure to HFD.
The IL-36 cytokine family has recently been shown to play a
role in the homoeostasis of the intestinal mucosa where it can act
opposingly to promote acute inflammation, as well as tissue
homoeostasis and resolution9,20,22,26. Interestingly, we found that
gene expression levels of Il36a and Il36b were constitutively
elevated in the colons of Il36rn−/− mice in the steady state. In
addition, activation of the MAPK (p42/p44) signalling pathway
was also found to be elevated in the colon, indicating enhanced
IL-36 receptor signalling in the colonic tissue microenvironment




















































































































































































Fig. 4 Altered composition of intestinal microbiome in Il36rn−/− mice dependent on IL-36 activity. a Relative gene expression of IL-36 cytokines and IL-36
receptor in the colon of wt and Il36rn−/− mice (n= 6 per group). b Protein expression of phospho-p44/p42 (Thr202/Tyr204, P-p44/P-p42) with total
p44/p42, and phospho-NF-κB p65 (Ser536, P-NF-κB p65) with total NF-κB p65, in the colons of wt (n= 3) and Il36rn−/− (n= 4) mice. c Weighted
ordination by principal coordinate analysis (PCoA) of beta-diversity of intestinal microbiome composition in wt and Il36rn−/− mice (n= 5 per group).
d Proportional relative abundance of the most abundant phyla in the microbiome of wt and Il36rn−/− mice. e Percent relative abundance means ± SD of
the eight most abundant phyla, Kruskal–Wallis rank sum test to determine significance. f Percent relative abundance of Akkermansia muciniphila in regard to
total bacteria in the microbiome of 8–10-week-old wt and Il36rn−/− mice, as determined by qPCR using specific primers, before (day −1) and after (days
6, 9) three i.p. injections of rIL-36Ra (n= 9 and 5) or PBS control (n= 9) (days 1, 2, 3) were performed . Data show means ± SEM unless otherwise
described. Statistical analysis using two-tailed Mann–Whitney test for (a) and (f), or as described. ns p > 0.05, *p < 0.05, **p < 0.01. Source data are
provided as a Source Data file
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the p65 subunit of NFκβ was found to be similarly high in both
wt and Il36rn−/− colon tissues, suggesting constitutive activity of
this pathway in the steady-state colon (Fig. 4b). The colonic gene
expression levels of several other inflammatory mediators
implicated in regulating intestinal inflammation and/or obesity
and metabolic disease, including Il1b, Tnfa, Il6, Il10 and Ifng,
were similar between wt and Il36rn−/− mice (Supplementary
Fig. 3a), indicating that loss of IL-36Ra expression did not lead to
a broad non-specific state of inflammation in the gut.
Furthermore, IL-6 and TNFα were also found to be expressed
at similar levels in the serum of wt and Il36rn−/− mice after
HFD, indicating that loss of IL-36Ra expression did not
significantly alter systemic inflammation and contribute to the
effects on weight gain and metabolism described (Supplementary
Fig. 3b, c).
Prompted by these observations and the emerging important
role for the intestinal microbiome in influencing the develop-
ment of obesity5,9, we investigated whether Il36rn deficiency
resulted in any alterations in the constituents of the intestinal
microbiome through 16S V4 rRNA gene sequencing. This
analysis revealed significant beta-diversity differences in the
overall composition of the intestinal microbiome between wt
and Il36rn−/− mice (PERMANOVA, p= 0.009), with weighted
ordination analysis based on Bray–Curtis dissimilarity values
showing clear separation according to genotype (Fig. 4c). At the
phylum level, the most striking difference observed was a
significant increase in the abundance of Verrucomicrobia (p=
0.01, Kruskal–Wallis rank sum test), which was found to be
>1600-fold more abundant in Il36rn−/− mice compared with
wt (15.2 ± 4.65% vs. 0.0091 ± 0.0114% relative abundance,
respectively) (Fig. 4d, e). Other phyla with significant, albeit
minor, differences in abundance were Cyanobacteria (enriched
in knockout), Tenericutes and Deferribacteres (enriched in wt)
(Fig. 4d, e). A deeper analysis of differentially detected
operational taxonomic units (OTU) at the genus/strain level,
identified Akkermansia muciniphila, a member of the Verru-
comicrobia phylum, as the most significantly enriched micro-
bial strain among those identified in the intestinal microbiome
of Il36rn−/− mice (p= 1.08 × 10−58) (Table 1). Recent
evidence indicates that A. muciniphila can play an important
protective role against obesity and metabolic dysfunction in
mice and may also play a similar role in humans11,12,16. The
relative outgrowth of this strain was confirmed through qPCR
of stool samples from an additional cohort of mice, using
specific primers for A. muciniphila, and universal bacteria
primers. Importantly, this relative outgrowth was found to be
specifically dependent on Il36rn deficiency and was lost upon
treatment of Il36rn−/− mice with recombinant IL-36Ra
(Fig. 4f). Three intraperitoneal injections of IL-36Ra on days
1, 2 and 3, led to gradually decreasing abundance levels of A.
muciniphila, similar to the levels observed in wt mice, as
detected by qPCR on days 6 and 9 (Fig. 4f). These data
demonstrate that loss of expression of the IL-36 receptor
antagonist results in enhanced IL-36 cytokine gene expression
in the colon and promotes the outgrowth of A. muciniphila in
the intestinal microbiome.
Increased mucus expression in the colons of Il36rn−/− mice.
We next sought to investigate what changes may be evident in the
colons of Il36rn−/− mice, which might influence the composi-
tion of the intestinal microbiome, and in particular the relative
outgrowth of A. muciniphila. A. muciniphila is a Gram-negative
anaerobe which colonises the mucus layer of the gastrointestinal
tract and degrades mucins as its predominant energy source27.
Histological examination of the colon of Il36rn−/− mice through
haematoxylin and eosin (H&E) and Alcian Blue/Periodic
acid–Schiff (AB/PAS) staining, revealed a significant increase in
the number of mucus-secreting goblet cells in the colon (Fig. 5a,
c). This increase was also accompanied by a thickening of the
outer mucus layer and significantly elevated expression of the
Muc2 gene (Fig. 5b, d, e), demonstrating that Il36rn deficiency
leads to increased production of mucus in the colon providing an
abundant source of nutrients to support the relative outgrowth of
A. muciniphila. Consistent with these changes, we also observed
improved intestinal barrier function in Il36rn−/− mice after
HFD, as demonstrated by decreased gut permeability to FITC-
dextran (Fig. 5f).
It has recently been reported that IL-36 can act to drive the
expression of IL-9 by CD4+ T cells in the colons of mice21 and
IL-9 has been previously reported to play a central role in
promoting goblet cell hyperplasia in the gut28. Interestingly, levels
of IL-9 secretion were found to be significantly increased in
colonic tissue from Il36rn−/− mice compared with wild-type
controls (Supplementary Fig. 4a). Secretion levels of IL-13 and IL-
22, which have, also, been implicated in driving goblet cell
differentiation29,30, were not found to be significantly altered
(Supplementary Fig. 4b, c).
To explore the mechanism through which enhanced IL-36
activity leads to increased mucus secretion in the colon, we
investigated whether administration of rIL-36Ra, which inhibited
the relative outgrowth of A. muciniphila (Fig. 4f), could also reverse
these changes. Interestingly, Il36rn−/− mice treated with rIL-36Ra
had decreased goblet cell numbers, that were comparable with those
of the wild-type mice (Fig. 6a, b). In contrast, treatment with an
anti-IL-9-neutralizing antibody did not alter goblet cell numbers in
Il36rn−/− mice, suggesting that elevated IL-9 expression does not
play a significant role (Supplementary Fig. 4d, e). Furthermore,
ex vivo stimulation of wild-type colon explants with IL-36α for 4 h
led to a significant increase in Muc2 gene expression, suggesting
that IL-36 cytokines can act directly to stimulate increased mucus
production (Fig. 6c). Together, these data confirm that IL-36
cytokines can alter the colonic tissue microenvironment to promote
the relative outgrowth of A. muciniphila.
Table 1 OTUs identified at strain level in the microbiome of wt and Il36rn−/− mice
OTU, genus Strain name Change observed Adj P-value
t__81483, g__94otu1084 Atopostipes suicloacalis Enriched in wild type 0.0151
t__284, g__Corynebacterium Corynebacterium ammoniagenes Enriched in wild type 0.00354
t__61727, g__Brachybacterium Brachybacterium sp. Lact5.2 Enriched in knockout 6.59×10−08
t__68330, g__Bacteroides Bacteroides acidifaciens Enriched in knockout 0.00281
t__43597, g__94otu20339 Alistipes shahii WAL 8301 Enriched in knockout 0.0176
t__40900, g__Flexispira Helicobacter mastomyrinus Enriched in wild type 2.22×10−05
t__78858, g__Akkermansia Akkermansia muciniphila ATCC BAA-835 Enriched in knockout 1.08×10−58
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The microbiome influences reduced obesity in Il36rn−/−mice.
In an effort to examine the influence of the altered intestinal
microbiome described above on the reduced weight gain and
metabolic dysfunction observed in the setting of Il36rn deficiency,
we sought to equilibrate the gut microbiome through prolonged
(8 weeks) cohousing of Il36rn−/− and wt mice in the same cage,
to investigate whether this altered the response to HFD exposure.
As previously reported in similar studies, cohousing of mice
resulted in a relative equalization of the constituents of the
intestinal microbiome31,32, as determined by analysis of beta-
diversity when compared with separately housed mice (PER-
MANOVA, p= 0.001). Weighted ordination analysis demon-
strated similar positional clustering for all cohoused mice in
contrast to separately housed mice which clustered according to
genotype (Fig. 7a). Critically, this equalisation coincided with a
complete loss of the relative outgrowth of the phylum Verruco-
microbia (0.149 ± 0.0367% relative abundance for Il36rn−/−,


































































































Fig. 5 Increased colon mucus levels and reduced intestinal permeability in Il36rn−/− mice. a Representative micrographs of distal colon sections from wt
and Il36rn−/− mice stained with H&E and AB/PAS. Scale bar= 1 μm. b Representative micrographs of colon sections stained with AB/PAS with mucus
layer (ML) indicated by red arrow. Scale bar= 20 μm. c, d Quantitation of average goblet cells per crypt (c) and mucus layer thickness (d) in distal colon
sections (n= 6 per group, 10 crypts measured per sample). Data shown representative of three independent experiments. e Relative gene expression of
Muc2 gene in the distal colon of wt and Il36rn−/− mice (n= 6 per group). f Fluorescein isothiocyanate (FITC)-dextran concentration in the serum of wt
and Il36rn−/− mice on HFD for 12 weeks, 4 h after oral gavage (n= 4 and 6 per group). Data show means ± SEM. Statistical analysis using two-tailed
unpaired student’s t-test. *p < 0.05, **p < 0.01. Source data are provided as a Source Data file
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demonstrated through relative OTU analysis and confirmed by
qPCR for A. muciniphila detection (Fig. 7b–d). Cohoused
Il36rn−/− mice exhibited a significant enrichment of Bacter-
oidetes, and decreased abundance of Actinobacteria when com-
pared with their cohoused wt counterparts, but none of the
previously differentially abundant phyla were found to be altered
in cohoused mice (Fig. 7b, c).
Strikingly, cohoused Il36rn−/− mice now exhibited similar
levels of weight gain, adipose tissue mass and glucose and insulin
intolerance when compared with their wild-type counterparts
upon exposure to HFD for 8–10 weeks (Fig. 7e–j). These data
demonstrate a clear association between the altered intestinal
microbiome observed in Il36rn−/− mice and their protection
from obesity and metabolic disease.
Discussion
Cytokines of the interleukin-1 family are emerging as one of the
most important mediators of obesity and metabolic health, with
diverse and often opposing roles in either driving inflammatory
mechanisms associated with disease pathogenesis, e.g. IL-1β, or
inhibiting inflammation and/or caloric intake to promote the
maintenance of metabolic health, e.g. IL-33, IL-18 and IL-3717,24.
Although the precise mechanisms through which members of the
IL-1 family exert these dichotomous effects are incompletely
understood, to date all members have been investigated for their
roles in disease with the exception of the IL-36 subfamily.
Similar to related IL-1 family members, expression of IL-36
cytokines, specifically IL-36γ, is elevated in the serum of obese
















































Fig. 6 IL-36 signalling increases goblet cell numbers and Muc2 gene expression. a, b Representative micrographs of AB/PAS-stained sections (a) and
average goblet cells per crypt quantitation (b) in the colon of wt and Il36rn−/− mice after (day 6) three consecutive injections (days 1, 2, 3) of rIL-36Ra or
PBS control (n= 4 and 5 per group). Scale bar= 1 μm. c Relative Muc2 gene expression in wt colon explants either untreated or stimulated for 4 h with
recombinant IL-36α (200 ng/ml). Data show means ± SEM. Statistical analysis using two-tailed unpaired student’s t-test. *p<0.05. Source data are
provided as a Source Data file
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correlated with primary indicators of metabolic health, i.e. HbA1c
and FBG levels, among obese patients presenting with diabetes,
indicating that elevated IL-36 cytokines may play a protective role
in reducing blood sugar levels among obese patients who have
developed consequent metabolic disease.
In an effort to explore mechanistically how the IL-36 family
might regulate obesity and metabolic disease, we investigated
what role, if any, these cytokines might play in disease patho-
genesis in mice with a deficiency in the IL-36 receptor antagonist
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revealed that constitutively hyperactive IL-36 cytokine activity
(Il36rn−/−) led to a significant reduction in weight gain and
adiposity, with improved glucose and insulin tolerance, without
altering food intake. These data demonstrate that elevated IL-36
family signalling plays a broadly similar protective role to related
IL-1 family members IL-18, IL-33 and IL-3733–36. In contrast to
what has been reported under settings of IL-18R or IL-33R
deficiency33,37, we observed that mice with a deficiency of the IL-
36 receptor (Il1rl2−/−) did not display any changes in adiposity
development after HFD, demonstrating that constitutive IL-36R
expression does not influence disease progression in this model
and suggesting that protection from disease is only evident under
conditions of elevated IL-36 family activity. In this regard, it is
interesting to note that elevated levels of IL-36α, β and γ are
found in the serum of a number of lean as well as obese indivi-
duals (Fig. 1), and it would be of interest to investigate whether
these patients are less susceptible to the development of obesity
and metabolic dysfunction.
Related IL-1 family members have previously been shown to
influence the development of insulin resistance, at least in part,
through altering the nature of adipose tissue inflammation17.
However, we did not observe any significant alterations in
immune cell infiltration in the adipose tissues of Il36rn−/− mice,
suggesting that this cytokine family may regulate obesity devel-
opment at a different tissue site. IL-36 cytokines are well estab-
lished as mediators of inflammation in psoriatic skin, and more
recently, as important regulators of homoeostasis at the gut
mucosa18. Prompted by these discoveries, and the emerging role
of the intestinal microbiome in regulating metabolic health, we
investigated whether IL-36 cytokines can alter the composition of
the intestinal microbiome, and identified a significant outgrowth
of the mucin-degrading bacterial strain Akkermansia muciniphila
in Il36rn−/− mice. A. muciniphila has recently emerged as an
important commensal which can protect against obesity and
metabolic disease in mice and has been associated with improved
health among obese patients11,12,16. Although the precise host
mechanisms through which the bacterium exerts these effects are
yet to be fully identified, our mouse data demonstrate that its
abundance is regulated by IL-36 family cytokines and indicate
that it plays a central role in mediating protection from disease in
Il36rn−/− mice. While alterations in the intestinal microbiome
have previously been described in studies using mice deficient in
related IL-1 family members, the significance of these findings in
relation to obesity and metabolic health has not been reported.
Indeed, two recent studies have found that IL-33 and IL-18,
which suppress obesity and metabolic dysfunction, can in fact act
to limit A. muciniphila abundance in mice under certain
settings32,38. This suggests that IL-36 cytokines act in a
mechanistically distinct fashion to protect from disease. In line
with this observation, while IL-18 has been reported to act to
suppress food intake in mice33, no such changes were observed in
Il36rn−/− mice in this study. It is also intriguing to note that IL-
18 has been reported to suppress the differentiation of mucus-
secreting goblet cells31, while Il36rn deficiency leads to increased
goblet cell numbers as well as increased mucus expression and
likely creates an environmental niche to support A. muciniphila
outgrowth17,27,39. Similarly, numerous studies have uncovered
prominent roles for both IL-18 and IL-33 in regulating the
homoeostasis of adipose tissue- resident immune cells, while no
such changes were found in Il36rn−/− mice in this study17.
While demonstrating novel protective effects against disease,
this study does not rule out a significant role for IL-36 cytokines
in having further, unidentified important mechanistic roles in
mediating these effects. In this regard, our observation that higher
IL-36γ levels are inversely associated with blood glucose levels
among diabetic patients is of particular significance and it would
be of interest to determine whether IL-36 cytokines can act
specifically to regulate glucose secretion/uptake among obese
patients. Similarly, it has previously been reported that IL-36
cytokines can act to suppress peroxisome proliferator-activated
receptor γ and perhaps restrict adipocyte differentiation
in vitro40. A further important consideration is the fact that
several of the obese diabetic patients included in our study were
under treatment with metformin which has previously also been
found to alter the composition of the intestinal microbiome in
diabetic patients and specifically increase the abundance of A.
muciniphila in the intestines of mice14,15. Therefore, a deeper
investigation of the effects of IL-36 activity in obese diabetic
patients is warranted.
IL-36 cytokines have been described as playing dichotomous
pro-inflammatory and pro-resolving roles across several tissue
sites, including the gut18. In this regard, it is possible that a
constitutive basal level of inflammation in Il36rn−/− mice may
play a confounding role in the phenotype described. However, it
is noteworthy that we were unable to detect any significant
changes in expression of inflammatory mediators implicated in
obesity-dependent metabolic disease, either in colonic tissue in
the steady state, or systemically in the serum after HFD exposure
(Supplementary Fig. 3).
In summary, our data provide novel insight into how IL-36
cytokines can act to regulate the pathogenesis of obesity and
metabolic disease and demonstrate for the first time their ability
to direct the composition of the intestinal microbiome towards a
more metabolically healthy state. Furthermore, these data provide
important new advances in understanding the dichotomous
nature of the broader IL-1 family as critical regulators of
inflammatory disease and identify the role of the intestinal
microbiome as an important regulator of these effects.
Methods
Human subjects. Serum samples were obtained from 104 adult donors, of whom 67
were classified as obese having a body mass index of ≥30 kg/m2. A clinical assess-
ment of all subjects was undertaken upon enrolment, and parameters including sex,
age, BMI, weight in kg, HbA1c, FBG, cholesterol, triglycerides, LDL and HDL, as well
as current medication use was recorded (Supplementary Table 1). Levels of human
IL-36 alpha, IL-36 beta, IL-36 gamma and IL-36Ra were measured in the sera of
patients using DuoSet ELISA kits (R&D Systems, Minneapolis, MN) according to the
Fig. 7 Microbiome analysis and obesity phenotype of cohoused wt and Il36rn−/− mice. a Weighted ordination analysis of beta-diversity of intestinal
microbiome composition in cohoused for 8 weeks and separately housed wt and Il36rn−/− mice (n= 5 per group). b Proportional relative abundance of
the most abundant phyla in the microbiome of cohoused wt and Il36rn−/− mice. c Percent relative abundance means ± SD of the eight most abundant
phyla (including unclassified phylum), Kruskal–Wallis rank sum test to determine significance. d Percent relative abundance of A. muciniphila in regard to
total bacteria before and after cohousing wt and Il36rn−/− mice for 4 and 8 weeks, as determined by qPCR (n= 4 per group). e–h Aged matched male wt
and Il36rn−/−mice were cohoused since weaning in the same cage for 8 weeks (n= 4 per group). They were then given HFD for 8–10 weeks, and weights
were monitored weekly (e). f EAT and SAT depots mass after 10 weeks in HFD. g, h GTT on cohoused mice after 8 weeks in HFD, glucose over time (g)
and AUC (h) shown. i–j ITT on cohoused mice after 9 weeks in HFD, glucose over time (i) and inverted AUC (j) shown. Data show means ± SEM unless
otherwise described. Statistical analysis using two-tailed Mann–Whitney test for d, two-tailed unpaired student’s t-test for (f), (h) and (j), RM two-way
ANOVA for (e), (g) and (i) or as described. ns p > 0.05, *p < 0.05, **p < 0.01. Source data are provided as a Source Data file
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manufacturer’s instructions, in a blinded fashion. For further analysis, obese subjects
were classified as type 2 diabetic using HbA1c ≥48mmol/mol as per WHO and ADA
guidelines25 or non-diabetic with HbA1c <48mmol/mol. Patients with controlled
diabetes, i.e. HbA1c <48mmol/mol, undergoing current antidiabetic therapy were
excluded from the study. Ethical approval for the human study was obtained from
the Ethics Committees at St. Vincent’s University Hospital Dublin, and all patients
and control subjects gave written, informed consent.
Mice. Wild-type (wt) and Il36rn−/− mice on C57BL/6 background were pre-
viously described19 and bred in-house. Il36rn−/− mice were rederived from het-
erozygotes in our facility. Il1rl2−/− mice on C57BL/6 background obtained from
Amgen under Material Transfer Agreement were described previously22. Male
mice were fed irradiated normal chow diet and weights were measured monthly
from 8 weeks of age; food and water intake was measured weekly. For diet-induced
obesity experiments, three independent cohorts of male mice were fed with a HFD
(60 kcal% fat, D12492i, Research Diets Inc.) for 8–12 weeks starting from 8 to
10 weeks of age, and weights and food intake were measured weekly. For cohousing
experiments, wt and Il36rn−/− mice were housed in the same cage at a 1:1 ratio
since weaning, for 8 weeks, before being given HFD for 8–10 weeks, their weights
measured weekly. To determine specificity of IL-36Ra effects on microbiome and
goblet cells, wt and Il36rn−/− mice were injected i.p. with recombinant IL-36Ra
(R&D Systems) (1.5 μg/mouse) on 3 consecutive days (days 1, 2, 3) and colon tissue
collected in formalin on day 6 for histology, or faecal pellets collected for DNA
extraction and bacteria detection using qPCR on days −1, 6 and 9. For IL-9
neutralisation experiments, wt and Il36rn−/− mice (n= 6–8 per group) were
administered by i.p. injection either with 100 μg/mouse anti-mouse IL-9 mono-
clonal antibody (InVivoMAb, clone 9C1, BioXCell) or isotype control (InVivoMab
mouse IgG2a isotype control, clone C1.18.4, BioXCell) every other day for 5 days
and colons were subsequently harvested for goblet cell enumeration. All animal
experiments were performed with ethical approval by TCD Animal Research Ethics
Committee and under license by the Irish Health Products Regulatory Authority
(project authorization no: AE19136/PO77).
Glucose and insulin tolerance tests. For glucose tolerance test, mice were
injected i.p. with 2 g/kg glucose (Sigma) after overnight fasting. For insulin toler-
ance test, they were injected i.p. with 1 U/kg insulin (recombinant human, Sigma)
after overnight fasting. Blood glucose was measured by submandibular bleeding at
defined time intervals, using handheld blood glucose monitor (On Call Vivid,
ACON Laboratories or FreeStyle Lite, Abbot Laboratories).
RNA extraction and real-time quantitative RT-PCR. Colon samples from wt and
Il36rn−/− mice were harvested and stored in RNAlater (Sigma) at −20 °C. Total
RNA was extracted using Isolate II RNA Mini Kit (Bioline, London, UK) after
tissue disruption using BeadBug homogenizer and 1.5 mm Zirconium beads
(Benchmark Scientific, Inc.). Reverse transcription was performed using High-
Capacity cDNA Kit (Applied Biosystems, Foster City, CA) following the manu-
facturer’s instructions, with 100 ng of total RNA per sample. Real-time PCR for the
indicated transcripts was performed in triplicate using specific TaqMan Gene
Expression Assays (Supplementary Table 2) and TaqMan Fast Universal PCR
Master Mix in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA). 18S ribosomal RNA was used for normalisation and relative expression
levels were calculated using the ΔΔCt method.
16S V4 rRNA gene sequencing for microbiome profiling. Intestinal microbiome
profiling analysis was performed by Second Genome Inc. (CA, USA). DNA iso-
lation from 10-week-old mouse fecal material was performed with the MoBio
PowerMag® Microbiome kit (Carlsbad, CA) according to the manufacturer’s
guidelines and optimised for high-throughput processing. All samples were
quantified via the Qubit® Quant-iT dsDNA High Sensitivity Kit (Invitrogen, Life
Technologies, Grand Island, NY) to ensure that they met minimum concentration
and mass of DNA. To enrich the sample for bacterial 16S V4 rDNA region, DNA
was amplified utilising fusion primers designed against the surrounding conserved
regions which are tailed with sequences to incorporate Illumina (San Diego, CA)
adapters and indexing barcodes. Each sample was PCR amplified with two dif-
ferently barcoded V4 fusion primers. Samples that met the post-PCR quantification
minimum were advanced for pooling and sequencing. For each sample, amplified
products were concentrated using a solid-phase reversible immobilisation method
for the purification of PCR products and quantified by qPCR. A pool containing
16S V4 enriched, amplified, barcoded samples were loaded into a MiSeq® reagent
cartridge, and then onto the instrument along with the flow cell. After cluster
formation on the MiSeq instrument, the amplicons were sequenced for 250 cycles
with custom primers designed for paired-end sequencing.
Second Genome’s analysis software package was used for statistical analysis.
Sequenced paired-end reads were merged using USEARCH and the resulting
sequences were compared with an in-house strain database using USEARCH
(usearch_global). All sequences hitting a unique strain with an identity ≥99% were
assigned a strain Operation Taxonomic Unit (OTU). To ensure specificity of the
strain hits, a difference of ≥0.25% between the identity of the best hit and the
second-best hit was required (e.g. 99.75 vs. 99.5). For each strain OTU, one of the
matching reads was selected as representative and all sequences were mapped by
USEARCH (usearch_global) against the strain OTU representatives to calculate
strain abundances. The remaining non-strain sequences were quality filtered and
dereplicated with USEARCH. The resulting unique sequences were then clustered
at 97% by UPARSE (de novo OTU clustering) and a representative consensus
sequence per de novo OTU was determined. The UPARSE clustering algorithm
comprises a chimera filtering and discards likely chimeric OTUs. All non-strain
sequences that passed the quality filtering were mapped to the representative
consensus sequences to generate an abundance table for de novo OTUs.
Representative OTU sequences were assigned taxonomic classification via mothur’s
bayesian classifier, trained against the Greengenes reference database of 16S rRNA
gene sequences clustered at 99%.
For beta-diversity analysis, abundance-weighted sample pairwise differences
were calculated using the Bray–Curtis dissimilarity. Principal coordinate analysis
(PCoA) was used to plot two-dimensional ordination. PCoA uses the sample-to-
sample dissimilarity values (beta-diversity) to position the points relative to each
other by maximising the linear correlation between the dissimilarity values and the
plot distances. Permutational analysis of variance (PERMANOVA) was utilised for
whole-microbiome significance testing of beta-diversity differences. For taxon
significance testing, univariate differential abundance of OTUs was tested using a
negative binomial noise model for the overdispersion and Poisson process intrinsic
to these data, as implemented in the DESeq2 package41, and described for
microbiome applications42. It takes into account both technical and biological
variability between experimental conditions. DESeq was run under default settings
and q-values were calculated with the Benjamini–Hochberg procedure to correct p-
values, controlling for false discovery rates.
Bacteria DNA extraction and quantitative PCR. DNA was extracted from mouse
faecal material after homogenisation with 1.5 mm zirconium beads using BeadBug
homogenizer (Benchmark Scientific, Inc.). DNA isolation was performed using
QiaAmp Fast DNA Stool Mini Kit (QIAGEN) following the manufacturer’s pro-
tocol. An amount of 10–20 ng of DNA was then used in qPCR reactions for A.
muciniphila with specific primers (AM1: CAGCACGTGAAGGTGGGGAC, AM2:
CCTTGCGGTTGGCTTCAGAT), and for total bacteria (UniF340: ACTCCTAC
GGGAGGCAGCAGT, UniR514: ATTACCGCGGCTGCTGGC) for normal-
isation. qPCR was performed in 7900HT Fast Real-Time PCR system using Fast
SYBR Green Master Mix (Applied Biosystems, Foster City, CA).
Histology and staining. Distal colon samples were fixed in 10% neutral buffered
formalin (Medical Supply, Mulhuddart, Dublin), or Carnoy’s solution for mucus
layer analysis, and embedded in paraffin. Blocks were sectioned in a microtome
and 5-μm thickness sections were mounted in Superfrost Plus adhesion slides
(Thermo Scientific, Braunschweig, Germany). Slides were stained with H&E and
AB/PAS for histological assessment and to enumerate goblet cells per crypt and
mucus layer thickness in the tissue.
Cytokines and insulin ELISA assays. Colon explants were cultured for 24 h
(37 °C, 5% CO2) to measure secretion of cytokines IL-9, IL-13 and IL-22 in the
supernatants using mouse uncoated ELISA kits (Invitrogen, Ready-SET-Go! ELISA
kits, eBioscience), or for 4 h in the presence of 200 ng/ml IL-36α to measure Muc2
mRNA expression. IL-6 and TNF-α were measured in the serum of mice after HFD
using mouse uncoated ELISA kits (Invitrogen, Ready-SET-Go! ELISA kits,
eBioscience). Levels of fasting plasma insulin were measured using Ultra Sensitive
Mouse Insulin ELISA Kit (Crystal Chem) according to the manufacturer’s
instructions.
Flow cytometry. Adipose tissue was digested with 1 mg/ml collagenase D, passed
through a cell strainer and red blood cells were lysed. Stromal vascular cells were
then stained for flow cytometric analysis using fluorophore-conjugated antibodies
specific for mouse CD45 (30-F11), F4/80 (BM8), CD11b (M1/70), CD11c (N418)
(eBioscience, Invitrogen) and CD301 (LOM-14) (BioLegend), and Aqua Live/Dead
stain (Invitrogen) to identify live-cell population. LSR Fortessa instrument (BD
Biosciences) was used and data were analysed using FlowJo software (TreeStar).
Cell enumeration was performed using CountBright Absolute Counting Beads for
flow cytometry (Invitrogen).
Western blotting. For insulin sensitivity assays, protein lysates were prepared
from liver, leg skeletal muscle and epididymal white adipose tissue harvested from
mice fed with a HFD for 8 weeks, 10 min after intraperitoneal challenge with 1.5 U/
kg insulin (recombinant human, Sigma), using RIPA Lysis Buffer System (Santa
Cruz). For analysis of signalling pathways downstream of IL-36 in colon tissues,
tissues were harvested from wt and Il36rn−/− mice and lysed in RIPA buffer.
Protein concentration was determined with Bicinchoninic Acid Kit for Protein
Determination (Sigma) and lysates were diluted with NuPAGE LDS Sample Buffer
and Reducing Agent (ThermoFisher Scientific) and heated for 10 min at 70 °C.
Samples were loaded on precast NuPAGE Novex 4–12% Bis-Tris gradient gels
(Invitrogen) or RunBlue Bis-Tris 4–12% gels (Expedeon) and SDS-PAGE was
performed in XCell SureLock Mini-Cell Electrophoresis system (ThermoFisher
Scientific) for 120 min at 100 V. Separated proteins were transferred to Invitrolon
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polyvinylidene fluoride (PVDF) membranes (ThermoFisher Scientific) for 1 h at
30 V, followed by blocking with 5% BSA or skimmed milk and incubation with
appropriate antibodies. Primary antibodies used were Phospho-NF-κB p65
(Ser536) (93H1) Rabbit mAb (1:1000, Cell Signaling), NF-κB p65 (C-20) Rabbit
polyclonal (1:1000, Santa Cruz), Phospho-AKT (S473) (D9E) XP Rabbit mAb
(1:1000, Cell Signaling), Akt (pan) (C67E7) Rabbit mAb (1:1000, Cell Signaling),
Phospho-p44/42 MAPK (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (1:1000,
Cell Signaling), p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (1:1000, Cell Sig-
naling), Phospho-IGF-I Receptor β (Tyr1135/1136)/Insulin Receptor β (Tyr1150/
1151) (19H7) Rabbit mAb (1:1000, Cell Signaling) and Insulin Receptor β (4B8)
Rabbit mAb (1:1000, Cell Signaling). Secondary antibody used was Goat anti-
Rabbit IgG (1:5000, Sigma) horseradish peroxidase conjugated. Blots were devel-
oped in FUSION-FX chemiluminescence system (Vilber) using SuperSignal™ West
Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific). Densitometry
analysis of immunoblots was performed using ImageJ software. Uncropped ver-
sions of blots can be found in the Source Data file.
FITC-dextran for intestinal permeability. Mice on a HFD for 12 weeks were
administered 20 mg/mouse FITC-dextran (Sigma) by oral gavage after overnight
fasting. After 4 h, blood was collected and serum was prepared. Serum was diluted
1/2 in PBS and fluorescence at 490/525 nm was measured, using the standard curve
of FITC-dextran and serum from control (non-gavaged) animal as blank to
determine FITC-dextran concentrations in serum.
Statistical analysis. Sample size for patient’s serum analysis and mouse studies
were chosen based on our published studies35,43. Analysis of cytokines in patients
serum was carried out in a blinded fashion and subsequently segregated based
upon clinical parameters. Analysis of data from mouse studies, i.e. goblet cell
enumeration was carried out in a blinded fashion. Statistical analysis of individual
data sets was performed by first analysing data sets for normal distribution
(Shapiro–Wilk and Kolmogorov–Smirnov test) and equality of variance (F test),
followed by unpaired two-tailed student’s t-test or Mann–Whitney test for non-
parametric data, as appropriate. For repeated measures analysis, RM two-way
ANOVA with Bonferroni post hoc test was used instead. Correlation analysis were
performed using Spearman’s correlation test. All analysis and graph representation
were performed using GraphPad Prism 6 software. Data are shown as means ±
SEM unless specified otherwise. All qPCR data were analysed using the
ΔΔCt method. Statistical details for each figure can be found in the figure
legends.
Data availability
All relevant data are available from the authors. Source data for all relevant figures
provided as a Source Data file. 16S sequence data are available through GenBank,
Accession Numbers MN211558–MN212548.
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